ESPR
HEALTHCAREEsperion Therapeutics Inc
AI Insight
What's Moving ESPR Today?
No stock-specific AI insight has been generated for ESPR yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.95$4.18
$3.16
Fundamentals
Market Cap$814M
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE-260.8%
Profit Margin-1.8%
Debt / Equity—
Trading
Volume5.6M
Avg Volume (10D)—
Shares Outstanding257.7M
ESPR News
22 articles- Esperion Therapeutics (ESPR) Stock Fair Value Moves Lower After Analyst DowngradesYahoo Finance·Jun 23, 2026
- Why Is Altimmune (ALT) Down 11.3% Since Last Earnings Report?Yahoo Finance·Jun 12, 2026
- Catalyst (CPRX) Up 0.6% Since Last Earnings Report: Can It Continue?Yahoo Finance·Jun 10, 2026
- Glazer Capital (ESPR) reports 20,975,620 shares, an 8.15% positionStock Titan·Jun 9, 2026
- Esperion Presents New Data from CLEAR Outcomes and the CLEAR PATH Phase 2 Pediatric Study at the European Atherosclerosis Society Congress 2026Yahoo Finance·May 26, 2026
- Esperion Therapeutics estimates U.S. heart failure costs at 46B dollars a year, urges therapy optimizationTraders Union·May 15, 2026
- Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)Yahoo Finance·May 14, 2026
- ESPR Stock Surges 44% in a Month: Here's What You Need to KnowYahoo Finance·May 14, 2026
- Esperion Announces Two New Analyses Supporting Bempedoic Acid to Reduce LDL-C Levels to be Presented at the European Atherosclerosis Society (EAS) Congress 2026Yahoo Finance·May 13, 2026
- ARCHIMED to acquire Esperion Therapeutics in $1.1 billion dealQz·May 1, 2026
- Summit’s ‘self-inflicted’ stumble; Esperion’s take-private dealBiopharmadive·May 1, 2026
- Esperion to be Acquired by ARCHIMEDYahoo Finance·May 1, 2026
- Esperion to Report First Quarter 2026 Financial Results on May 7Yahoo Finance·Apr 23, 2026
- Esperion Therapeutics Highlights 38% Revenue Growth, Enbumyst Launch Plan at Needham ConferenceMarketbeat·Apr 13, 2026
- Esperion Therapeutics (ESPR) Down 10% Since Last Earnings Report: Can It Rebound?Yahoo Finance·Apr 9, 2026
- Athyrium Capital Management and Esperion Enter Into $50 Million Japan Royalty Financing to Support Strategic Acquisition of Corstasis TherapeuticsBenzinga·Apr 2, 2026
- Esperion Therapeutics Closes Acquisition of Corstasis Therapeutics, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)GlobeNewswire Inc.·Apr 2, 2026
- Esperion to Participate in 25th Annual Needham Virtual Healthcare ConferenceYahoo Finance·Mar 31, 2026
- Esperion Showcases New Data from CLEAR Outcomes Highlighting Value of NEXLETOL® (bempedoic acid) at the American College of Cardiology’s Annual Scientific Session 2026Yahoo Finance·Mar 30, 2026
- Karyopharm Therapeutics (KPTI) Stock Jumps 6.9%: Will It Continue to Soar?Yahoo Finance·Mar 27, 2026
- Esperion (ESPR) Highlights Inclusion of Bempedoic Acid in 2026 ACC/AHA Dyslipidemia GuidelinesYahoo Finance·Mar 20, 2026
- Esperion to Present Two New Analyses from CLEAR Outcomes Clinical Trial at the American College of Cardiology 2026 Annual Scientific SessionYahoo Finance·Mar 17, 2026
All 22 articles loaded
Price Data
Open$3.16
Previous Close$3.16
Day High$3.17
Day Low$3.15
52 Week High$4.18
52 Week Low$0.95
52-Week Range
$0.95$4.18
$3.16
Fundamentals
Market Cap$814M
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE-260.8%
Profit Margin-1.8%
Debt / Equity—
Trading
Volume5.6M
Avg Volume (10D)—
Shares Outstanding257.7M
About Esperion Therapeutics Inc
Esperion Therapeutics, Inc., a pharmaceutical company, develops and markets drugs for the treatment of patients with high low-density lipoprotein cholesterol in the United States and internationally. The company is headquartered in Ann Arbor, Michigan.
HEALTHCAREDRUG MANUFACTURERS - SPECIALTY & GENERIC
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICDRUG MANUFACTURERS - SPECIALTY & GENERIC
CIK—
Composite FIGI—
Share Class FIGI—